Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 3
2(33.3%)
6Total
Phase 1(4)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03016819Phase 3Recruiting

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Role: lead

NCT07392736Phase 1Recruiting

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

Role: lead

NCT04165330Phase 1Active Not Recruiting

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Role: collaborator

NCT06794957Phase 1Active Not Recruiting

A Study of AL8326 in Non-Small Cell Lung Cancer

Role: lead

NCT02584478Phase 3Unknown

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Role: lead

NCT05612191Unknown

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Role: lead

NCT02558348Phase 1Terminated

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

Role: lead

All 7 trials loaded